MMMajd Machour

Majd Machour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Majd Machour has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A stiff bioink for hybrid bioprinting of vascularized bone tissue with enhanced mechanical properties

    by Majd Machour, Roy Meretzki, Yuval Moshe Haizler, Margarita Shuhmaher, Dina Safina, Mark M. Levy, Shulamit Levenberg


  • Open Access

    Bioprinting Perfusable and Vascularized Skeletal Muscle Flaps for the Treatment of Volumetric Muscle Loss

    by Eliana O. Fischer, Anna Tsukerman, Majd Machour, Margarita Shuhmaher, Asaf Silverstein, Maya Yaakov, Orit Bar‐Am, Lior Debbi, Shulamit Levenberg

    Volumetric muscle loss (VML) refers to muscle tissue loss exceeding 20% within a functional area due to trauma or surgery, often leading to physical disabilities. VML treatment relies on the transplantation of autologous flaps harvested from a healthy‐donor site while minimizing the probability of immune rejection. However, this approach often leads to donor‐site morbidity and relies on a restricted supply of muscle tissue. Current solutions in tissue engineering focus on engineered grafts lacking hierarchical vasculature with a feeding vessel, thus limited by diffusion. This study expanded upon a new approach of multimodal bioprinting which enabled the fabrication of thick hierarchical vascular muscle flaps composed of bioprinted and vascularized skeletal muscle tissue, and a 3D‐printed engineered macrovessel, which successfully repaired VML injury in‐vivo. The flaps are implanted by anastomosing the macrovessel via microsurgery to the femoral artery in proximity to an induced VML injury in Sprague‐Dawley rat hindlimbs. Immediate perfusion of the flaps is demonstrated, as is flap endurance to physiological blood pressure, flow, and shear stress. Flap implantation enhanced myocyte differentiation, and vascular ingrowth and facilitated tissue viability and integration. These results obtained by utilizing human‐origin cells provide a foundation for fabricating patient‐specific flaps for the treatment of extensive soft tissue defects.


  • Emulsion-templated macroporous polycaprolactone: Synthesis, degradation, additive manufacturing, and cell-growth

    by Bar Shlomo-Avitan, Majd Machour, Samah Saied Ahmad, Yoav Friedler, Shulamit Levenberg, Michael S. Silverstein


  • Open Access

    Placenta‐Derived Mesenchymal Stromal‐Like Cells Promote 3D‐Engineered Muscle Tissue Differentiation and Vessel Network Maturation

    by Anna Tsukerman, Majd Machour, Margarita Shuhmaher, Eliana O. Fischer, Hagit Shoyhet, Orit Bar‐Am, Gali Guterman Ram, Lior Debbi, Dina Safina, Shulamit Levenberg


  • Open Access

    Placenta‐Derived Mesenchymal Stromal‐Like Cells Promote 3D‐Engineered Muscle Tissue Differentiation and Vessel Network Maturation

    by Anna Tsukerman, Majd Machour, Margarita Shuhmaher, Eliana O. Fischer, Hagit Shoyhet, Orit Bar‐Am, Gali Guterman Ram, Lior Debbi, Dina Safina, Shulamit Levenberg

    Placental‐derived stromal‐like cells (PLX‐PAD) have been shown to facilitate muscle tissue recovery after injury and stimulate angiogenesis. This work assesses the impact of PLX‐PAD cells on the vascularization and maturation of engineered skeletal muscle tissue. Specifically, their effects in direct co‐culture with endothelial cells, pericytes, and myoblasts seeded within microporous 3D scaffolds are characterized. Additionally, the impact of hypoxic PLX‐PAD cell‐conditioned medium (CM) on vascularization and muscle differentiation of engineered tissue is monitored. Co‐culture of PLX‐PAD with myocytes stimulated myocyte differentiation while PLX‐PAD CM promoted the formation of vascular networks. Implantation of a multi‐culture system of vascularized human skeletal muscle tissue and PLX‐PAD into a rectus abdominal defect in nude mice promoted myocyte differentiation, host vessel penetration, and tissue integration. These findings indicate the ability of placenta‐derived cells to induce the formation of vascularized engineered muscle constructs with potential therapeutic applications.


  • Open Access

    Ultrasound Mediated Polymerization for Cell Delivery, Drug Delivery, and 3D Printing

    by Lior Debbi, Majd Machour, Daniel Dahis, Hagit Shoyhet, Margarita Shuhmaher, Ruth Potter, Yael Tabory, Idit Goldfracht, Itiel Dennis, Tom Blechman, et al.

    Safe and accurate in situ delivery of biocompatible materials is a fundamental requirement for many biomedical applications. These include sustained and local drug release, implantation of acellular biocompatible scaffolds, and transplantation of cells and engineered tissues for functional restoration of damaged tissues and organs. The common practice today includes highly invasive operations with major risks of surgical complications including adjacent tissue damage, infections, and long healing periods. In this work, a novel non‐invasive delivery method is presented for scaffold, cells, and drug delivery deep into the body to target inner tissues. This technology is based on acousto‐sensitive materials which are polymerized by ultrasound induction through an external transducer in a rapid and local fashion without additional photoinitiators or precursors. The applicability of this technology is demonstrated for viable and functional cell delivery, for drug delivery with sustained release profiles, and for 3D printing. Moreover, the mechanical properties of the delivered scaffold can be tuned to the desired target tissue as well as controlling the drug release profile. This promising technology may shift the paradigm for local and non‐invasive material delivery approach in many clinical applications as well as a new printing method – “acousto‐printing” for 3D printing and in situ bioprinting.


  • Open Access

    Print‐and‐Grow within a Novel Support Material for 3D Bioprinting and Post‐Printing Tissue Growth

    by Majd Machour, Noy Hen, Idit Goldfracht, Dina Safina, Maya Davidovich‐Pinhas, Havazelet Bianco‐Peled, Shulamit Levenberg

    3D bioprinting holds great promise for tissue engineering, with extrusion bioprinting in suspended hydrogels becoming the leading bioprinting technique in recent years. In this method, living cells are incorporated within bioinks, extruded layer by layer into a granular support material followed by gelation of the bioink through diverse cross‐linking mechanisms. This approach offers high fidelity and precise fabrication of complex structures mimicking living tissue properties. However, the transition of cell mass mixed with the bioink into functional native‐like tissue requires post‐printing cultivation in vitro. An often‐overlooked drawback of 3D bioprinting is the nonuniform shrinkage and deformation of printed constructs during the post‐printing tissue maturation period, leading to highly variable engineered constructs with unpredictable size and shape. This limitation poses a challenge for the technology to meet applicative requirements. A novel technology of “print‐and‐grow,” involving 3D bioprinting and subsequent cultivation in κ‐Carrageenan‐based microgels (CarGrow) for days is presented. CarGrow enhances the long‐term structural stability of the printed objects by providing mechanical support. Moreover, this technology provides a possibility for live imaging to monitor tissue maturation. The “print‐and‐grow” method demonstrates accurate bioprinting with high tissue viability and functionality while preserving the construct's shape and size.


  • Open Access

    A micro-channel array in a tissue engineered vessel graft guides vascular morphogenesis for anastomosis with self-assembled vascular networks

    by Barak Zohar, Lior Debbi, Majd Machour, Netta Nachum, Idan Redenski, Mark Epshtein, Netanel Korin, Shulamit Levenberg